Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Exostoses-anetodermia-brachydactyly type E syndrome is an association reported in a single kindred characterized by the variable presence of the following features: anetodermia (macular atrophy of the skin), multiple exostoses, and brachydactyly type E. There have been no further descriptions in the literature since 1985.
Features include: Multiple exostoses, Dermal atrophy, and Type E brachydactyly.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 1 | Dermal atrophy |
Biomarker and diagnostic research for exostoses-anetodermia-brachydactyly type E syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for exostoses-anetodermia-brachydactyly type E syndrome.
201 publications have been identified in PubMed for exostoses-anetodermia-brachydactyly type E syndrome. Kisho has analyzed 62 by research type. Research spans Review / Meta-Analysis (66%), Basic Science / Preclinical (13%), and Case Report / Case Series (6%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 41 | 66% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 6:00 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research |
8 |
13% |
Patient case studies | 4 | 6% |
Disease patterns and progression | 4 | 6% |
Other research | 2 | 3% |
Testing and diagnosis research | 2 | 3% |
New treatment approaches | 1 | 2% |
Fullin J (2026). [PMID: 41407825](https://pubmed.ncbi.nlm.nih.gov/41407825/). *Leukemia*. [Basic Science / Preclinical]
Anders HJ (2026). [PMID: 41071671](https://pubmed.ncbi.nlm.nih.gov/41071671/). *J Am Soc Nephrol*. [Review / Meta-Analysis]
Varghese D (2026). [PMID: 41520798](https://pubmed.ncbi.nlm.nih.gov/41520798/). *Surv Ophthalmol*. [Case Report / Case Series]
Kihara K (2026). [PMID: 42156031](https://pubmed.ncbi.nlm.nih.gov/42156031/). *Brain Nerve*. [Review / Meta-Analysis]
Monahan G (2026). [PMID: 41031626](https://pubmed.ncbi.nlm.nih.gov/41031626/). *J Bone Miner Res*. [Case Report / Case Series]
Salunke DD (2025). [PMID: 40511242](https://pubmed.ncbi.nlm.nih.gov/40511242/). *J Pharm Bioallied Sci*. [Review / Meta-Analysis]
Moore AR (2025). [PMID: 41028543](https://pubmed.ncbi.nlm.nih.gov/41028543/). *Nat Med*. [Review / Meta-Analysis]
Lin F (2025). [PMID: 40624665](https://pubmed.ncbi.nlm.nih.gov/40624665/). *Biomed Eng Online*. [Review / Meta-Analysis]
Gallegos FR (2025). [PMID: 39803890](https://pubmed.ncbi.nlm.nih.gov/39803890/). *Am J Hypertens*. [Review / Meta-Analysis]
Carroll RS (2025). [PMID: 40581356](https://pubmed.ncbi.nlm.nih.gov/40581356/). *J Bone Miner Res*. [Basic Science / Preclinical]